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1. Abbreviations 
ACS  acute coronary syndrome 
ACTH  adrenocorticotropic hormone 
ANOVA analysis of variance 
BDI  Beck Depression Inventory 
BMI  body mass index 
BSCI  Rahe’s Brief Stress and Coping Inventory 
CAD  coronary artery disease 
CgA  chromogranin A 
CK  creatine kinase 
CRH  corticotropin-releasing hormone 
CRP  C-reactive protein 
CV  coefficient of variation 
ECG  electrocardiography / electrocardiogram 
ELISA  enzyme-linked immunosorbent assay 
FITC  fluorescein isothiocyanate 
HDL  high density lipoprotein 
HPA  hypothalamic-pituitary-adrenocortical 
IL-6  interleukin-6 
LDL  low density lipoprotein 
MFI  mean fluorescence intensity 
MI  myocardial infarction 
MLR  monocyte-to-lymphocyte ratio 
NYHA New York Heart Association 
n.a.  not available 
n.s.  not significant 
PCI  percutaneous coronary intervention 
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PNI  psycho-neuroendocrino-inflammatory / 
psycho-neuro-immune / psycho-neuro-immunology / 
psycho-neuro-inflammatory  
post-PCI directly after percutaneous coronary intervention 
pre-PCI directly before percutaneous coronary intervention 
r  correlation coefficient 
SAM / SAS sympathetic-adrenomedullary system 
SAP  stable angina pectoris 
SEM  standard error of the mean 
SD  standard deviation 
SNS  sympathetic nervous system 
TBS  tris-buffered saline 
TMB  3,3’,5,5’-tetramethylbenzidine 
TNF-α  tumour necrosis factor-alpha 
1d-PCI on the following day of PCI 
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2. Summary 
Background. Psychosocial stress and depression are becoming widely recognized as major risk 
factors for coronary artery disease (CAD). Although both neutrophil granulocytes and 
monocytes are known as principal contributors to atherosclerosis, their associations with 
psycho-neuroendocrino-inflammatory (PNI) factors have not been fully revealed in CAD 
patients to date.  
Objectives. Our aims were to examine cortisol- and ACTH-based alterations in granulocyte 
activation in stable and acute CAD patients undergoing percutaneous coronary intervention 
(PCI) and to study the correlations between the monocyte-to-lymphocyte ratio (MLR) and key 
PNI markers in stable CAD patients. 
Methods. In study I., blood samples of 21 stable angina pectoris (SAP) and 20 acute coronary 
syndrome (ACS) patients were collected directly before (pre-PCI), after (post-PCI) and on the 
following day of PCI (1d-PCI). Granulocyte surface L-selectin, CD15 and (neutrophil-specific) 
lactoferrin were assayed by flow cytometry. Plasma cortisol, ACTH, lactoferrin and IL-6 were 
also analysed. In study II., 23 stable CAD patients participated who completed the Beck 
Depression Inventory (BDI) and Rahe’s Brief Stress and Coping Inventory. A white blood cell 
differential and determinations of cortisol, chromogranin A (CgA), LL-37, interleukin-6 (IL-
6), and C-reactive protein (CRP) levels were carried out in plasma. 
Results. In study I., pre- and post-PCI percentages of lactoferrin-carrying neutrophils were high 
and decreased markedly next day in both patient groups; similarly, 1d-PCI plasma lactoferrin 
values were about half of the post-PCI values (all: p≤0.0001). Post-PCI ACTH reduced 
significantly one day after stenting, especially in ACS group (SAP: p<0.01, ACS: p≤0.0001). 
In ACS patients, the increased pre-PCI cortisol level decreased substantially the next day after 
stenting (p<0.01); in pre-PCI samples of this group, cortisol correlated with plasma lactoferrin 
(r~0.5, p<0.05). In 1d-PCI samples of both groups, ACTH associated negatively with the ratio 
of lactoferrin-bearing neutrophils (SAP: r= -0.601, p<0.005; ACS: r= -0.541, p<0.05) and with 
plasma lactoferrin (SAP: r = -0.435, p<0.05; ACS: r = -0.609, p<0.005).  
In study II., elevated monocyte fraction, MLR and plasma CgA levels characterized the stable 
CAD patients. Social support score was low and BDI scores of seven patients were increased. 
In the multivariate-adjusted analysis, the MLR correlated with depressive symptom severity 
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(r=0.624, p<0.01), plasma CgA (r=0.660, p<0.01), LL-37 (r=0.643, p<0.01), IL-6 (r=0.532, 
p<0.05), and CRP values (r=0.470, p<0.05). Higher BDI scores associated with higher 
concentrations of CgA (r=0.618, p<0.01), and CgA level correlated inversely with social 
support score (r= -0.511, p<0.05).  
Conclusions. In stable and acute CAD patients, both pre- and post-PCI states could be 
associated with increased ratio of activated/degranulated neutrophils shown by the elevated 
lactoferrin parameters, which declined the next day of PCI indicating a substantial decrease in 
neutrophil activation. The 1d-PCI lactoferrin values were associated negatively with plasma 
ACTH in both CAD groups. In the ACS group, before stenting, a correlation of cortisol with 
plasma lactoferrin was found, that could reflect an association of cortisol with neutrofil 
activation in extremely stressed CAD patients. We suggest that plasma lactoferrin might be 
considered as a ‘neutrophil activity sensor’ in CAD. 
In stable CAD patients, increased MLR may be associated with depressive symptoms, with 
increased neuroendocrino-sympathetic activity and with inflammatory factors that are probably 
involved in the initiation and development of atherosclerosis. The elevated neuroendocrino-
sympathetic activity correlated with low social support and with depressive symptom severity. 
The MLR could serve as a simple, inexpensive, broadly available PNI correlate marker in stable 
CAD. 
 
 
 
 
 
Keywords:  
ACTH, acute coronary syndrome, atherosclerosis, coronary artery disease, cortisol, depressive 
symptoms, inflammation/inflammatory factors, lactoferrin, monocyte-to-lymphocyte ratio, 
neutrophil activation, psychological stress, psycho-neuro-immunology, social support, stable 
coronary artery disease, stenting  
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3. Introduction 
3.1. Coronary artery disease 
 It is widely known, that 
coronary artery disease (CAD) is 
among the three leading causes of death 
in most countries worldwide [1-3]. 
Although its mortality rate reduced 
since the latter part of the 20th century 
− mainly due to the advancement in 
both prevention and treatment (e.g. by 
introduction of percutaneous coronary 
intervention /PCI/) −, it is expected to 
remain the number 2 killer in 2030 
worldwide, closely after cancer (Fig. 1) 
[4-7]. 
 
 
Figure 1. Cardiovascular disease (CVD) remains the grim reaper’s primary calling card, but 
people can take steps to keep the world’s number one killer at bay. 
(Cannon B (2013) Cardiovascular disease: Biochemistry to behaviour. Nature 493:S2-3. doi:10.1038/493S2a.) 
Traditionally, the main risk factors of CAD are partly life style factors: imbalanced diet, 
physical inactivity − and as a consequence of them: metabolic syndrome with abdominal 
obesity, dyslipoproteinemia, hypertension and insulin resistance (type 2 diabetes mellitus) and 
in addition, cigarette smoking; other risk factors include age, gender and genetic factors. The 
recognition of novel, psychological risk factors, like psychosocial stress and depression, is also 
emerging in CAD; these conditions have gained much interest as potential key players in 
coronary atherosclerosis [1,3,8]. 
Basically, CAD occurs as a consequence of atherosclerosis of the coronary arteries, 
which leads to limited blood flow and results in an imbalance between myocardial oxygen 
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demand and supply. This hypoxia is responsible for angina pectoris symptoms, which may vary, 
but are mainly squeezing chest pain and/or referred pain that may radiate typically into the left 
arm, shoulder, back neck or jaw [9]. CAD can be classified to stable angina and acute coronary 
syndromes, the latter one may be further divided into three subgroups: unstable angina, non-ST 
elevation myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI) 
(Fig. 2) [10]. 
 In stable angina, pain generally occurs predictably with exertional activity and resolves 
with rest or sublingual administration of nitroglycerin [9]. (Only the most serious stable cases 
are characterized by symptoms at rest). Unstable angina, a form of acute coronary syndromes, 
refers to an angina that changes or worsens 
and can be described with a severe new-onset 
chest pain, occurs at rest or shows a crescendo 
pattern, or it may indicate a threatening 
myocardial infarction. The 
pathophysiological process of NSTEMI is 
similar to unstable angina, except it is 
associated with microembolization and 
cardiomyocyte necrosis (indicated by 
elevated biomarker values) [10]. In the 
presence of electrocardiographic evidence for 
ST elevation, myocardial infarction can be 
diagnosed as STEMI. 
Figure 2. Spectrum of coronary artery disease. ACS = acute coronary syndrome. 
(Braunwald E (2012) Unstable angina and non-ST elevation myocardial infarction. Am J Respir Crit Care Med 
185:924-932. doi:10.1164/rccm.201109-1745CI.) 
Myocardial infarction (MI) is classically defined as myocardial cell death owing to 
extended ischemia and caused predominantly by fibrous cap rupture and thrombus formation 
(MI type 1, 70% of acute myocardial infarctions) [11]. 
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Beside assessing the pattern of angina in symptomatic CAD patients, the main tools of 
differential diagnosis include electrocardiography (ECG), echocardiography, coronary 
angiography and biomarker testing. Recording an ECG and performing an echocardiogram at 
rest are routine diagnostic tests for all (suspected) CAD patients. Momentarily asymptomatic 
stable patients may perform an exercise stress test on a treadmill or a stationary cycle ergometer 
to get a 12-lead exercise ECG [12]. Coronary angiography (Fig. 3) is a minimally invasive 
technic to assess coronary circulation, to 
identify the nature of the coronary lesion and to 
check whether the patient is suitable for 
percutaneous coronary intervention (PCI) or 
coronary artery bypass graft (CABG) surgery. 
Coronary angiography is performed with a 
tube-like catheter, which is led to the trunk of 
one of the coronary arteries and when in place, 
a radiocontrast dye is injected into the coronary 
blood to make the blood flow visible on the X-
ray motion picture. 
Figure 3. Coronary angiogram demonstrating occluded arteries. 
(Gladding PA, Cave A, Zareian M, Smith K, Hussan J, et al. (2013) Open access integrated therapeutic and 
diagnostic platforms for personalized cardiovascular medicine. J Pers Med 3:203-237. doi:10.3390/jpm3030203.) 
3.2. The process of atherosclerosis – main points 
Atherosclerosis is a multifocal, chronic inflammatory disease of the medium-sized and 
large arteries and it is the main underlying cause of coronary artery disease. According to 
autopsy studies, initial steps in the pathogenesis of atherosclerosis starts at young age and 
develops silently over decades before it leads to serious cardio- and cerebrovascular 
consequences [13]. Atherosclerosis alone remains rarely fatal; it is the superimposed 
thrombosis on the surface of an eroded or ruptured atherosclerotic plaque, that generally triggers 
the well-known life-threatening cardiovascular events such as acute coronary syndromes or 
stroke. Key players in the development of atherosclerosis are endothelial cells, leukocytes, and 
intimal smooth muscle cells (Fig. 4). 
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On the very onset of this disease, endothelial dysfunction develops due to certain 
atherogenic factors (e.g. oxidative stress caused by smoking); then smaller plasma molecules 
and lipoprotein particles get through the leaky and defective endothelium into the 
subendothelial space. There, they get bound to proteoglycans in the basement membrane, 
accumulate, undergo an oxidative modification and become proinflammatory. Specifically, the 
oxidized LDL is the most significant proatherogenic contributor to the initiation of 
atherosclerosis. The mechanisms responsible for its formation from LDL is not fully known, 
although one of the possible triggers could be myeloperoxidase, which is most abundantly 
derived from neutrophil granulocytes [14,15]. 
As a result of proinflammatory stimuli, endothelium becomes activated, upregulates the 
expression of adhesion receptors – e.g. E-selectin, P-selectin and vascular cell adhesion 
molecule-1 (VCAM-1), and recruits primarily monocytes and T-cells – according to the 
traditional view. Cell surface upregulation of additional adhesion receptors (e.g. intercellular 
adhesion molecule-1 /ICAM-1/), contribute to the further adhesion of blood-borne cells to the 
atherosclerotic lesion [16]. After transendothelial migration into the intima, monocytes 
differentiate into macrophages, phagocyte the proatherogenic lipoproteins via scavenger 
receptors and become fully lipid-loaded foam cells containing a huge amount of cholesteryl 
ester. However, a reverse cholesterol transport through the plasma membrane to extracellular 
HDL and to the liver is also possible under certain conditions [15,17,18]. 
The scavenger receptors are not down-regulated after cellular cholesterol accumulation, 
therefore, the endless supply of proinflammatory lipoproteins leads to the overloading and 
consequently, to the death of these leukocytes. Mass apoptosis of macrophages contributes to 
the formation of soft lipid-rich core in the lesion called the fatty streak, which is still 
asymptomatic, although activation and death of macrophages results in the release of a great 
variety of inflammatory, chemotactic and growth factors (IL-1β, IL-6, IL-12, TNF-α) [19]. 
In further steps of the progression of atherosclerosis, intimal smooth muscle cells 
mediate a fibroproliferative response to heal the inflamed and injured artery that leads to plaque 
formation. Although, when a prolonged inflammation persists, this reparative response could 
backfire and beside providing stability to plaques against rupture and thrombosis, contributes 
to the narrowing of the lumen and leads to reduced blood flow and ischemia [20,21]. 
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Figure 4. Pathogenesis of atherosclerosis. 
(Steinl DC, Kaufmann BA (2015) Ultrasound imaging for risk assessment in atherosclerosis. Int J Mol Sci. 
16:9749-9769. doi:10.3390/ijms16059749.) 
However, when a plaque would grow big enough to limit the lumen diameter 
significantly, remodelling of the artery takes place to maintain a nearly normal lumen and 
additional, hypoxia-induced formation of collaterals will occur. Therefore, a close to 100% 
stenosis is possible almost with no symptoms (in case of well-developed collaterals). 
Neovascularization is common in more advanced, high risk atherosclerotic plaques and is a 
hallmark of persisting inflammation in site. Through contributing to extravasation of 
inflammatory cells and erythrocytes, these new leaky and fragile microvessels are connected to 
rapid plaque development [22,23]. 
Loss of smooth muscle cells by apoptosis or necrosis results in a thin, fragile fibrous 
cap and consequently leads to the development of a rupture-prone vulnerable/unstable plaque 
that is characterized by a large lipid core with high macrophage content and microvessel 
density, intraplaque hemorrhage and superimposed thrombus formation. In contrast, stable 
plaques have a smaller lipid core with a significantly lower macrophage content, fewer 
microvessels and a thicker fibrous cap; therefore, rupture and superimposed thrombus 
formation is not characteristic of them (Fig. 5) [24]. 
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Figure 5. Schematic overview of a stable atherosclerotic plaque (left) and an unstable 
atherosclerotic plaque (right). 
(W van Lammeren G, L Moll F, Borst GJ, de Kleijn DP, P M de Vries JP, et al. (2011) Atherosclerotic plaque 
biomarkers: beyond the horizon of the vulnerable plaque. Curr Cardiol Rev 7:22-27. 
doi:10.2174/157340311795677680.) 
Although highly rupture-prone plaques responsible for most acute coronary syndromes 
are typically larger than those found in the background of stable angina, narrowing of the 
arterial lumen is usually more predominant in stable angina owing to the slow, constructive 
remodelling of the vessel wall [25]. 
Plaques commonly calcificate with aging; degree of this calcification is considered as a 
traditional marker of coronary plaque burden and linked to the disease prognosis [26]. In acute 
coronary syndromes, culprit lesions seem to be less calcified compared to plaques causing 
stable angina [27,28].  
Endothel dysfunction also contributes to the formation of a prothrombic environment 
that favours platelet activation and fibrin deposition onto the inflamed endothelium. Further 
destabilization of the plaque leads to the rupture of the weakened fibrous cap and ends in the 
formation of atherothrombus: the released extracellular matrix molecules initiate coagulation 
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and platelet recruitment [29,30]. Plaque rupture is common and it is the most frequent cause of 
coronary artery thrombosis; although mostly nonfatal, it contributes substantially to rapid 
development of the lesion [18]. 
3.3. Roles of neutrophils and monocytes in coronary artery disease 
Although neutrophils have received only a little attention in connection with 
atherosclerosis until lately, it is becoming widely-known by now that they participate actively 
not only in the very onset, but also in the progression of atherosclerosis [31-34]. They take part 
in early atherosclerosis through the release of myeloperoxidase form their azurophilic granules 
and thus, contribute to the proatherogenic oxidative modification of LDL [33]. Furthermore, 
neutrophils promote monocyte/macrophage recruitment into the lesion and take part in the 
thinning of the fibrous cap and formation of a vulnerable plaque both directly (e.g. via their 
derived proteinases) and through activating macrophages [32]. Interestingly, it was found that 
granulocytes are already primed in hyperlipidemic patients and any second trigger may fully 
activate them; this results in the release of superoxide radicals and inflammatory mediators that 
contributes to oxidative stress and inflammation, hence they can be considered as a risk factor 
for promoting atherosclerosis [35]. Moreover, alfa-defensins, which are neutrophil peptides, 
could also take part in cardiovascular inflammation [36]. 
Several studies showed that high neutrophil count or neutrophil-to-lymphocyte ratio is 
associated with coronary stenosis, and may predict CAD and major adverse cardiac events such 
as myocardial infarction [37-42]. Neutrophil activation is widely observed in unstable angina 
[43,44], however, the state of neutrophils in stable angina pectoris patients appears to be 
controversial [31,45] and requires more investigation. Activation state of neutrophils can be 
assessed by detecting cell surface lactoferrin, L-selectin and/or CD15 parameters, as their 
increased appearance on the cell surface can be considered as a sign of cell activation. From 
these, only lactoferrin can be considered as a specific neutrophil activation marker, its 
appearance on neutrophil cell surface and in blood plasma reflects degranulation that leads to 
its release from secondary granules to the circulation following activation [46-48]. 
Lactoferrin is an iron-binding glycoprotein that can be characteristically found in the 
secondary granules of the neutrophil granulocytes, in addition to blood plasma and several body 
fluids. Beside its antibacterial, antifungal and antiviral activities, it takes part in 
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immunomodulation: it modulates the maturation, migration and functions of immune cells. 
Lactoferrin may act as a cytokine-like proinflammatory factor and it can induce the expression 
of adhesion molecules on the surface of endothelial cells [49].  
L-selectin is a cell-cell adhesion receptor that is continually expressed in leukocyte 
plasma membrane and takes part in the regulation of early leukocyte trafficking, for example 
in neutrophil rolling. Since the cell surface appearance of this adhesion receptor can undergo 
dynamic changes upon leukocyte activation, therefore, it can be used as a marker of the 
granulocyte activation state [50]. 
CD15 (or Lewis X) is a carbohydrate adhesion ligand for selectins present on the plasma 
membrane and in the azurophilic granules of mature neutrophils; it is also expressed by several 
other leukocytes and epithel cells [51]. Activation of neutrophils induces its translocation from 
intracellular position to the cell surface [52], it takes part in the cell-cell interactions, the 
phagocytosis and the respiratory burst of neutrophils [51]. 
As mentioned above, activated monocytes and macrophages have a central role in the 
initiation and progression of atherosclerosis through foam cell formation and inflammatory 
factor production [53,54]. Monocyte count may predict the severity of atherosclerotic stenosis 
and coronary plaque progression in acute coronary syndromes [41,55]. Moreover, Waterhouse 
et al. (2008) suggested that of all white blood cell types, monocyte count has the strongest 
positive and independent relationship with CAD risk in asymptomatic adults [56]. According 
to a recent paper, decreased lymphocyte-to-monocyte ratio – i.e. an elevated monocyte-to-
lymphocyte ratio (MLR) – was associated with the prevalence of CAD and prior myocardial 
infarction, and represents a high risk for critical limb ischemia [57]. Lymphopenia (low 
lymphocyte count) is associated with increased risk of developing myocardial infarction and 
long-term all-cause mortality in patients with acute chest pain but without other diagnostic 
criteria for major cardiac events [58]. 
Interestingly, while an extensive literature can be found on the neutrophil-to-
lymphocyte ratio in connection with CAD, only very few papers were published on the clinical 
importance of the monocyte-to-lymphocyte ratio in atherosclerosis and especially in CAD. 
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3.4. Psychosocial stress and coronary artery disease (psycho-neuro-immunology) 
Psychosocial stress (e.g. social isolation, workplace stress or childhood abuse) and 
depression are becoming increasingly recognized as major risk factors for incident coronary 
artery disease and as independent predictors of poor cardiac prognosis [4,8,59-62]. While social 
isolation and low social support are known as risk factors for developing CAD, low scores in 
meaning of life is associated with increased risk of CAD mortality [59,62-64]. It is worth noting 
that stress could result in developing both depression and CAD [60]. 
Psycho-neuro-immunology (PNI) is a relatively new field of research investigating the 
interactions between stress, the nervous and immune system and health outcomes [65]. When 
facing with any kind of physical or emotional stressors, organisms respond with the ‘general 
adaptation syndrome’ characterized by Selye [66]. This adaptation is governed primarily by the 
sympathetic-adrenomedullary system (SAM/SAS) and the hypothalamic-pituitary-
adrenocortical (HPA) axis (Fig. 6) and leads to quantitative and qualitative alteration in immune 
functions [67,68]. In stress response, the activity of the sympathetic nervous system (SNS) 
results in the release of catecholamines: adrenaline (epinephrine) and, to a lesser extent, 
noradrenaline (norepinephrine) from the adrenal medulla. Furthermore, a direct connection or 
‘hard-wiring’ also exists between the SNS and lymphoid organs [69]. The other principal 
system involved in stress state is the HPA axis, which acts via corticotropin-releasing hormone 
(CRH), adrenocorticotropic hormone (ACTH) and cortisol.  
Although, cortisol and its analogues are well-known and widely used for their anti-
inflammatory and immunosuppressive effect, morning plasma cortisol levels were found to 
correlate with the severity of coronary atherosclerosis in US Air Force aircrew members and in 
patients with suspected CAD [70,71]. In addition, Hamer et al. reported that a heightened 
cortisol response to psychosocial stress associated with coronary artery calcification in healthy 
individuals [72]. 
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Figure 6. Schematic representation of the hypothalamo-pituitary adrenal (HPA) axis (with its 
negative feedback regulation). 
(Tilbrook AJ, Clarke IJ (2006) Neuroendocrine mechanisms of innate states of attenuated responsiveness of the 
hypothalamo-pituitary adrenal axis to stress. Front Neuroendocrinol 27:285-307. doi:10.1016/j.yfrne.2006.06.002.) 
Among the wide range of cell surface receptors, neutrophils have specific glucocorticoid 
receptors as well, that can affect their behaviour and homeostasis [32,34,73]. In fact, not only 
neutrophils, but the majority of the immune cells (e.g. monocytes) have stress hormone 
receptors (e.g. adrenergic receptors). Several stress hormones (e.g. glucocorticoids, 
catecholamines, CRH) exert immunomodulatory effects that can result in cytokine production, 
such as interferon-γ (IFN-γ), various interleukins (IL-1, IL-2, IL-6) and tumour-necrosis factor 
(TNF) by these target cells [68]. In turn, these cytokines may act back on the hypothalamus and 
may augment its activity even more; especially IL-6 was found to be a highly potent stimulator 
of HPA axis [60,67,74]. Merging the above discussed effects: psychological, neuroendocrine 
and inflammatory systems could interact with each other. As it could be seen, in the psycho-
15 
 
 
neuro-inflammatory network of atherosclerosis, neutrophils and monocytes/macrophages 
probably have fundamental roles: these leukocytes may potentially promote the initiation and 
progression of CAD by translating the activation of neuroendocrine system into inflammation 
in stressed (and hyper- /dyslipidemic) conditions. 
Thus, not surprisingly, psychological stress was found to lead to the activation of 
neutrophils, while relaxation resulted in its attenuation in anxious patients and even in healthy 
individuals [75-77]. It is known that patients with acute coronary syndrome are usually highly 
stressed, experience anger or depression; moreover, stable CAD patients also feel tension before 
or during PCI [78]. Neutrophil activation state, however, has been largely unexplored from the 
aspect of psycho-neuroendocrine background in patients undergoing PCI. 
Similarly, only few studies have investigated associations between monocyte 
counts/fractions and psychological factors in CAD. Gidron et al. (2003) found that an elevated 
monocyte fraction was related to lower social support and more life event stress in patients with 
acute coronary syndrome [79]; however, our knowledge in connection with stable CAD is still 
incomplete from the PNI aspect. 
Chromogranin A (CgA) is an acidic protein that is co-stored and co-released with 
catecholamines and produced by the diffuse endocrine and neuroendocrine system, its increased 
plasma levels could indicate general neuroendocrine overactivity including elevated 
sympathoadrenal activity [80,81]. Additionally, plasma CgA is considered as an independent 
predictor of mortality and heart failure in and after acute CAD, which is due to its production 
by the overloaded myocardium [82]. Recently, salivary CgA level has been suggested as a 
decent biomarker of psychosocial stress [83,84], anxiety [85-87] and depression [87,88]. 
3.5. Blood plasma inflammatory factors in CAD 
Cytokines are small proteins that have a central importance in the PNI system. 
Proinflammatory cytokines (especially IL-1, IL-6 and TNF-α) take part not only in the process 
of atherosclerosis and CAD, but also in inducing stress and depression. [59,89]. IL-6, which is 
produced mostly by monocytes, lymphocytes, fibroblasts and endothelial cells [90], is a main 
regulator of the systemic inflammatory response and it is a potent inducer of the acute phase 
reaction. During this process, the liver synthetizes C-reactive protein (CRP), which is a widely 
used systemic inflammatory marker in routine laboratory diagnostics. Both IL-6 and CRP are 
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considered as major biomarkers of vascular inflammation in CAD [91]. Furthermore, it was 
shown that plasma IL-6 and CRP are elevated in psychosocial stress and depression [92,93]. 
Neutrophils produce several kinds of cytokines, such as the proinflammatory IL-1, IL-
6 and TNF-α, and the immunomodulatory IL-8 [94]. On the other hand, they are affected by 
several cytokines; accordingly, various cytokine/chemokine receptors are present in their 
plasma membrane [95]. Stenting could trigger rapid, transient neutrophil activation, which is 
followed by the production of IL-6 and IL-8 in unstable angina [96]. Similarly, cytokine levels 
may increase after PCI in stable angina, as well [97]. 
Recent studies showed that LL-37, the only member of the human antimicrobial 
cathelicidin family, participates in inflammation and atherosclerosis. It can be expressed by 
monocytes/macrophages, neutrophils, natural killer cells and epithel cells [98-100]. It was 
found that LL-37 could be produced also by macrophages in atherosclerotic lesions [98,101]. 
LL-37 provides a chemotactic effect: induces angiogenesis via endothel cell activation and 
inflammatory cell recruitment to the atherosclerotic plaque [102].  However, LL-37 can also be 
anti-inflammatory according to the microenvironment [103]. 
Lactoferrin, a specific activation marker of the neutrophil cell surface, can gain access 
to the blood and can be regarded as a soluble inflammatory marker as well; its appearance in 
plasma reflects neutrophil activation/degranulation, which results in the release of 
proinflammatory cytokines in addition to oxygen radicals [46].  
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4. Aims 
From the aspect of psycho-neuroendocrine background, our knowledge is still 
incomplete on the activation state of neutrophils in CAD. Since neutrophils have a fundamental 
role in coronary atherosclerosis, it is considerably important to reveal the possible stress-related 
regulation of their activation in CAD patients before and after stenting. While participation of 
monocytes/macrophages in atherosclerosis is well-known, associations of the monocyte-to-
lymphocyte ratio with the psycho-neuro-immune network are largely unexplored in CAD. 
Therefore, in our studies, we were particularly interested in the PNI characteristics of 
our CAD patients and in the potential associations among stress markers, depressive symptoms 
and inflammatory markers with a special focus on neutrophil activation state and the monocyte-
to-lymphocyte ratio.  
More precisely, we set out to the following investigations: 
 
Study I.: in SAP and ACS patients, in connection with PCI (before, directly after and 
the next day of PCI) 
- assessment of the psycho-neuroendocrino-immune state (stress hormones: ACTH 
and cortisol, and a general inflammatory marker: IL-6; all tested in plasma) 
- analysis of the activation state of granulocytes (cell surface markers: L-selectin, 
CD15 and neutrophil-specific lactoferrin; plasma lactoferrin) 
- examination of the possible associations between granulocyte (neutrophil) 
activation markers and stress markers (plasma ACTH and cortisol) 
 
Study II.: in SAP patients: cross-sectional investigations 
- analysis of the associations of the MLR with neuroendocrine markers (cortisol and 
CgA), inflammatory parameters (IL-6, CRP, LL-37) and psychosocial factors 
(depressive symptoms and stress-coping scores) 
- investigations on further associations of the PNI network: among psychological 
factors, inflammatory parameters and neuroendocrine markers 
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5. Materials and methods 
5.1. Patients 
Study participants were recruited into two separate studies. In both studies, all 
participants gave a written consent to be enrolled in the study. The investigations conformed to 
the principles of the Declaration of Helsinki. The study protocols were approved in advance by 
the Regional Medical Ethics Committee (Human Investigation Review Board, University of 
Szeged, Albert Szent-Györgyi Clinical Centre; Ref. No: 37/2005 (for study I.),  Ref. No: 49/B-
125/2008, 2382 (for study II.) 
In study I., patients were eligible for inclusion if they had the characteristic symptoms 
of either stable angina pectoris (SAP) confirmed by a positive ergometric stress test or acute 
coronary syndrome (ACS). 25 patients with SAP and 20 patients with ACS were recruited and 
enrolled; however, our study involved only 41 subjects (21 SAP and 20 ACS) because 4 SAP 
patients’ blood samples were not suitable for processing (as a consequence of blood clotting 
disturbances and sample handling problems). In the ACS group, 6 patients had unstable angina, 
14 were diagnosed with acute myocardial infarction. Additional requirement for inclusion was 
the presence of at least one significant coronary artery stenosis (diameter >50%), which was 
demonstrated by coronary angiography as suggested by Videm et al. (2007) [45]. Clopidogrel 
(600 mg loading dose, 75-150 mg maintenance dose) before and after PCI was administered to 
all patients, as well as heparin (70-100 IU/kg) during PCI.  
During the procedure of PCI, a thin and flexible catheter with an inflatable balloon 
mounted very close to its tip is inserted into the radial (or femoral) artery and navigated towards 
the heart, where the critically narrowed coronary artery can be found. When it reaches the site 
of stenosis, the balloon covered with a stent inflates that compresses the plaque into the 
coronary wall and restores normal lumen and blood flow. The balloon is then deflated and 
withdrawn from the coronary system, but the implanted stent stays in the artery and supports 
the stretched artery wall (Fig. 7). 
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Figure 7. Coronary artery with stent 
(http://www.cpmc.org) 
 
 In study II., 23 patients with stable CAD participated. They had to have confirmed 
significant stenosis (diameter >50%) at least in two major coronary arteries to be included. The 
severity of heart failure symptoms of the patients was graded according to the New York Heart 
Association functional classification (NYHA, grades I-IV). Three (13%), four (17%), and five 
(22%) patients were in NYHA groups I, II, and III, respectively. 
 
Table 1. General characteristics of the patient groups 
Variable 
Study I. Study II. 
SAP ACS 
p 
stable CAD 
n=21 n=20 n=23 
Age (y) 64.1 ± 10.3 63.2 ± 13.6 0.81 62.87 ± 10.59 
Male gender (n, %) 13 (61.9) 14 (70.0) 0.74 18 (78) 
BMI (kg/m2) n.a. n.a. n.a. 28.80 ± 4.00 
Current smoking (n, %) n.a. n.a. n.a. 2 (9) 
Diabetes mellitus type II (n, %) 5 (23.8) 6 (30.0) 0.73 8 (35) 
Hypertension (n, %) 16 (76.2) 16 (80.0) 1.00 20 (87) 
Statins use (n, %) 16 (76.2) 15 (75.0) 1.00 21 (91) 
Antihypertensives use (n, %) 21 (100) 17 (85.0) 0.11 22 (96) 
Sedatives use (n, %) 7 (33.3) 7 (35.0) 1.00 9 (39) 
Proton pump inhibitors use (n,%) n.a. n.a. n.a. 16 (70) 
SAP: stable angina pectoris, ACS: acute coronary syndrome, CAD: coronary artery disease, n.a.: not 
available. Age and BMI are shown as mean ± SD. 
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In both studies, exclusion criteria covered prior bypass surgery, cardiogenic shock, 
malignancy (e.g. prostate cancer), immunological disorders (e.g. rheumatoid arthritis, chronic 
atrophic gastritis Type A), acute inflammations, treatment with immunosuppressive or anti-
inflammatory drugs (exception: low-dose aspirin, which was administered to all patients), 
recent major trauma or surgery, drug or alcohol abuse and poor mental function. Additional 
exclusion criteria in study II. was impaired renal function. None of the patients took 
antidepressants and/or H2-receptor blocker medication. Patient characteristics of both studies 
are shown in Table 1.  
5.2. Blood sampling and laboratory methods 
 Fasting venous blood samples were collected immediately before PCI (pre-PCI), 
immediately after PCI (post-PCI) and on the following day of PCI (1d-PCI) between 8-9 a.m. 
in study I.; in study II. samples were obtained 1 day before PCI between 7-10 a.m. The mean 
time of PCI was 45 min (range: 30 min-1 hour).  
 Blood collection for routine blood analysis was carried out at admission for the acute 
patient group (study I.); and before admission for stable patients (in both studies) to check the 
exclusion criteria. Creatine kinase (CK) values were measured in 1d-PCI samples in both 
studies to monitor heart attack in acute patients and to observe the occurrence of acute 
procedural myocardial infarction in stable patients. Cardiac troponin T was measured with a 
qualitative dry chemistry test using heparinized whole blood and was checked visually. 
Blood cell counts, total cholesterol, triglycerides, HDL-cholesterol and high sensitivity 
CRP (in study II. only) were determined in automatic analyzers and/or with commercial kits 
(Roche); LDL-cholesterol was calculated according to the Friedewald formula. Reference 
ranges: total leukocyte count: 3.9-11.1 109/l, neutrophil fraction: 44.0-68.0%, neutrophil count: 
1.7-6.1 109/l, monocyte fraction: 5-7%, monocyte count: 0.2-0.6 109/l, lymphocyte fraction: 27-
34%, lymphocyte count: 1.0-3.2 109/l, total cholesterol: <5.2 mmol/l, triglycerides: <2.0 
mmol/l, HDL-cholesterol: >1.0 mmol/l, LDL-cholesterol: <3.0 mmol/l, CK activity: <200 U/l, 
CRP: <5.0 mg/l. For study II., monocyte count was divided by the lymphocyte count to get the 
MLR; since no reference interval was available for it, we used the ratio of the median values of 
the monocyte and lymphocyte reference ranges (counts) as reference: 0.19. 
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5.2.1. Special plasma marker assays 
 We collected blood into cooled (4°C) EDTA-Vacutainer tubes, and stored plasma in 
aliquots in -80°C for special analyses. 
5.2.1.1. Neuroendocrine (stress) markers 
In study I., ACTH and cortisol were measured as stress markers, in study II., in addition 
to cortisol, CgA was applied as a neuroendocrine marker. 
ACTH concentrations were measured by a chemiluminescent assay (LKAC1, Immulite 
1000; Siemens Healthcare Diagnostics, UK; intra- and inter-assay CVs: 6.1% and 9.4%, 
respectively; reference range: <60 pg/ml). Cortisol was tested by radioimmunoassay (DSL-
2100; Diagnostic Systems Laboratories, Webster, TX; intra- and inter-assay CVs: 12%; 
reference range: 160-620 nmol/l). Chromogranin A was analysed with a radioimmunoassay kit 
(CGA-RIA CT; CIS Bio International, Gif-sur-Yvette, France; intra- and inter-assay CVs: 7%; 
reference range: 23-153 ng/ml). 
5.2.1.2. Inflammatory parameters 
 In study I., lactoferrin and IL-6, in study II., IL-6 and LL-37 plasma concentrations were 
determined as special inflammatory markers (in blood plasma). 
For the assessment of lactoferrin, an ‘in-house’ ELISA kit was applied, which was 
developed according to Antonsen et al. (1993) [104]. Briefly, microplate wells were coated for 
overnight with rabbit anti-human lactoferrin antibodies (3.7 mg/l; Dako, Denmark) at 4°C. 
After two washing steps, duplicate plasma samples were applied (ten-fold dilution in wells), 
and incubated for 1 h at room temperature. After washing five times, anti-lactoferrin-peroxidase 
was added into wells and incubated for another 1 h at room temperature (4000-fold dilution in 
wells). The conjugate was prepared from Dako antibody and from horseradish peroxidase 
(Calbiochem, USA) according to Wilson and Nakane (1987) [105]. After further washing steps, 
TMB (BD Biosciences, USA) was used to develop plates and 4N sulphuric acid to stop the 
reaction. Human lactoferrin (Sigma, USA) was used as standard, the stock solution (40 µg/ml, 
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in TBS-glycerol, stored at -20º C) was diluted in TBS-Tween prior application. Reference 
range/median for plasma lactoferrin: 40-200/90 ng/ml [104]. 
IL-6 was assayed by a commercial ELISA module set containing matched antibody 
pairs (BMS213/2MST; Bender MedSystems GmbH, Vienna, Austria) in study I., while in study 
II. a high sensitivity ELISA kit (BMS213HS; Bender MedSystems GmbH, Vienna, Austria; 
intra- and inter-assay CVs: 4.95% and 6.0%, respectively; reference range: <8.7 pg/ml) was 
used. LL-37 concentration was measured by an ELISA kit (HK321, Hycult Biotech Inc., Uden, 
the Netherlands; intra- and inter-assay CVs: 10%; reference range: 25-250 ng/ml). 
5.2.2. Determination of surface granulocyte activation markers (study I.) 
 L-selectin, CD15 and lactoferrin surface granulocyte activation markers were measured 
by flow cytometry using an indirect immunofluorescent method; the process of labelling and 
haemolysis was started within 2 hours after blood collection. The protocol was performed 
according to Keresztes et al. (2007) [76]. Since it is known that cell isolation techniques activate 
leukocytes, thus, whole blood samples were used. Whole blood aliquots (100 µl) were treated 
with (20 µl) saturating concentrations of a polyclonal anti-lactoferrin antibody (200 mg/l, ICN), 
a monoclonal anti-L-selectin (47 mg/l, Dako) or a monoclonal anti-CD15 antibody (8.5 mg/l, 
Dako). Negative controls contained normal rabbit serum or isotype-specific normal mouse Ig 
(Dako). After incubation for 20 min at room temperature and washing two times with Hank’s 
solution, sedimentation was carried out in Eppendorf tubes (using Heraeus Biofuge pico, 13000 
rpm). Within 1 hour after drawing blood, immunostaining was initiated with appropriate 
secondary antibodies: anti-rabbit (10 mg/l) or anti-mouse (20 mg/l) antibodies labelled with 
FITC (Dako) were added to the blood cells (20 µl aliquots of reagents to 180 µl aliquots of 
blood cells). Following incubation and further washing steps (carried out as before), hemolysis 
was performed using a lysis buffer (Lysing kit; Biodesign, USA). One millilitre of lysis reagent 
was added to a 100 µl aliquot of blood cells; after vigorous vortexing and 15 min incubation, 
sedimentation (6000 rpm) and a washing step (Hank’s solution) followed. Finally, blood cells 
were resuspended in 200 µl Hank’s buffer. 
Analyses were performed using a FACStar Plus Becton Dickinson equipment; only the 
granulocyte population was tested from leukocytes. Granulocytes were gated according to their 
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typically high forward- (FS) and side-scatter (SS) characteristics; they could be easily separated 
from lymphocytes and monocytes – the two other leukocyte populations in the flow cytometry 
analysis. (The side scatter is associated with the granularity of the cell; the forward scatter is 
related to the diameter of the cell.) Granulocytes with lactoferrin expressed on their surface 
were identified as activated neutrophils, because lactoferrin is specific for neutrophils and can 
get the cell surface only after degranulation followed by cell activation [46-48]. 10 000 
events/tube were recorded in granulocyte populations. Standard equipment calibrations 
preceded all measurements and proper negative controls were used to set the background 
intensity level before each detection series were determined. Ratios of labelled granulocytes (% 
of granulocytes bearing labelled markers on cell surface) and mean fluorescence intensities 
(MFI, associated to mean quantity of labelled molecules/cells) were calculated. Figure A8 
(annex section) shows examples of the performed flow cytometry analyses. 
5.3. Psychosocial measures (study II.) 
 We used the Hungarian version of the 21-item Beck Depression Inventory (BDI) to 
measure the severity of the depressive symptoms of patients [106,107]. Study participants rate 
every item on a scale from 0 to 3. Total score results may show no clinically relevant depressive 
symptoms (0-9), mild (10-18), moderate (19-25) or severe (25-63) depressive symptoms. 
 We applied Rahe’s Brief Stress and Coping Inventory (BSCI, a multidimensional self-
describing device) to evaluate everyday stress level and coping capacity [108]. In order to 
receive the global stress coping score, total stress score is subtracted from total coping score. 
According to the validated Hungarian version of the inventory, total scores may represent 
worrisome/non-sufficient (-15 to -5), sufficient (-4 to -1), good (0 to 4) and very good (5-15) 
global stress-coping capacity [109].  Both stress and coping scales contain 5 subscales. Coping 
subscales measure health habits, social support, responses to stress, life satisfactions, and 
purpose and connection. Specifically, the social support subscale measures the degree of a 
subject’s social network; the purpose and connection subscale (also called meaning of life) 
shows to what extent participants feel their life ‘worth living’ and it includes also a component 
of spirituality/religious attitude [64]. Subscale scores range between 0 and 14 (social support) 
or 16 (life meaning) and indicate worrisome/non-sufficient (0-7), sufficient (8-10), good (11-
13), or very good/excellent (14-16) coping with psychosocial stress. 
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5.4. Statistical analysis 
Continuous variables are presented as mean ± standard deviation (SD); two-sample 
Student’s t test was used to compare the general characteristics of the groups in study I. 
Categorical variables are shown as number of subjects (n) and percentage (%), and the groups 
were compared by Fisher’s exact test. Data distribution was checked by Kolmogorov-Smirnov 
statistics; data that did not show normal distribution were log-transformed before further 
analyses (ACTH in study I., the MLR, CRP and BDI score in study II.). All tests were two-
sided with a significance level of p<0.05. 
In study I., figures are presented as mean ± standard error of the means (SEM). Two-
way repeated measurements ANOVA was applied for over time comparisons (pre-PCI, post-
PCI, and 1d-PCI samples). Two main factors were considered in the analysis: the time (pre-
PCI, post-PCI and 1d-PCI) as within group (‘intragroup’) factor for repeated measurements and 
the two subject groups as between-subject (‘intergroup’) factor for independent samples; p 
values were for overall intragroup p, between groups/intergroup p, and one for their interaction. 
Significant value of interaction and special cases, when its value was relatively low: 0.3>p>0.05 
(the presence of interaction was assumed) allowed also between-group (SAP vs ACS) 
comparisons at each time point. Significant value of the separate intragroup p allowed further 
pairwise comparisons of the repeated measurements within each group. All the pairwise 
comparisons are modified t-tests, these and the separate intragroup p-s were calculated by the 
software based on estimated marginal means. To keep the familywise type I error rate on α=0.05 
level, we used the step-down Bonferroni adjustment for multiple comparisons. We used a mixed 
model to assess the change in the variances of repeated measures over time and at the same 
time, to take account of the possible correlation of the responses measured on the same subject. 
We chose a general unstructured form for within-subject variance covariance matrix, 
heterogeneity of group-variances was also taken into account. 
Spearman’s coefficient of correlation and its significance were calculated to assess the 
relationship between the stress hormones and selected inflammatory markers. Statistical 
analyses were performed using IBM-SPSS (version 15.0, SPSS Inc., Chicago, IL, USA) and 
SAS (v9.1, SAS institute, Cary, NC) softwares. 
In study II. we first calculated the necessary sample size to achieve clinically meaningful 
correlation coefficients of r ≥0.6 between variables of interest with a power of 80% and α=0.05 
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level of significance. The power analysis resulted a sample size of n=19 patients. For the 
compensation of potential dropouts, we recruited 24 patients; as one patient was transferred to 
another hospital, 23 subjects left to participate in our study. According to Cohen’s guidelines, 
effect size of correlation coefficients (r) with values of 0.1, 0.3 and 0.5 could be interpreted as 
small, medium and large, respectively [110]. Correlation coefficients with values ≥0.6, 
therefore, highly likely show existing associations between the tested variables regardless of p-
values, and even when performing multiple tests.  
In this still growing field of research, Bonferroni adjustment carries the risk of deriving 
truly important differences nonsignificant [111]. We decided not to adjust p-values for multiple 
comparisons as a consequence of that we hypothesized significant associations between the 
MLR and psychological factors, neuroendocrine and inflammation markers [112]. Secondary 
hypotheses were also defined for significant association amongst psychosocial factors, 
neuroendocrine and inflammation markers (except the MLR).  
We used bivariate and multivariate Pearson correlation analyses with adjustment for 
age, sex and BMI in order to examine the associations of the MLR with psychosocial factors, 
neuroendocrine and inflammatory markers; and similarly, to estimate the associations among 
psychosocial factors and neuroendocrine and inflammatory markers. Additionally, we adjusted 
CgA models for intake of proton pump inhibitors and NYHA grades, as this medication could 
elevate CgA levels and in heart failure CgA could also be elevated [82,113]. Models with BDI 
scores were additionally corrected for sedative use, as intake of sedatives influenced 
significantly on BDI scores among our patients. Statistical analyses were carried out using IBM-
SPSS software (version 20.0, SPSS Inc., Chicago, IL, USA). 
6. Results 
6.1. Routine blood data 
 In study I., we found that in the ACS group, patients had slightly elevated LDL-
cholesterol levels and markedly increased CK activity. Other significant between-group 
differences were not revealed and all other tested laboratory parameters were within the normal 
range.  
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 In study II., we found that the monocyte fraction (8.68 ± 2.97%) exceeded the maximal 
reference value (7%), and monocyte count came close to the upper reference limit; in the same 
time, lymphocyte fraction approached the minimal reference value. Therefore, the MLR yielded 
a considerably high value (0.32 ± 0.14) and exceeded the predefined reference value of 0.19. 
We observed normal values for the other white blood cells and blood lipids except for slightly 
elevated triglyceride levels. CRP was close to its upper reference limit (4.93 ± 5.27 mg/l). 
Routine blood data of the patients are shown in Table 2. 
 
Table 2. Routine blood data of the patient groups (Variables are means ± SD) 
Variable 
Study I. Study II. 
SAP ACS 
p 
stable CAD 
n=21 n=20 n=23 
Total leukocyte count (G/l) 7.02 ± 1.41 8.37 ± 3.02 0.08 6.73 ± 1.22 
Neutrophil granulocyte count (G/l) n.a. n.a. n.a. 4.05 ± 1.04 
Neutrophil granulocyte fraction (%) 62.62 ± 7.46 65.83 ± 8.18 0.2 59.70 ± 6.86 
Monocyte count (G/l) n.a. n.a. n.a. 0.58 ± 0.23 
Monocyte fraction (%) n.a. n.a. n.a. 8.68 ± 2.97 
Lymphocyte count (G/l) n.a. n.a. n.a. 1.90 ± 0.41 
Lymphocyte fraction (%) n.a. n.a. n.a. 28.82 ± 6.30 
Cholesterol (mmol/l) 4.34 ± 1.28 5.01 ± 1.10 0.11 4.30 ± 1.35 
HDL-Cholesterol (mmol/l) 1.29 ± 0.45 1.30 ± 0.41 0.95 1.18 ± 0.32 
LDL-Cholesterol (mmol/l) 2.36 ± 1.04 3.13 ± 1.04 0.043* 2.27 ± 0.94 
Triglycerides (mmol/l) 1.60 ± 0.62 1.35 ± 1.01 0.36 2.04 ± 1.25 
CK (U/l) 175.0 ± 286.6 669.8 ± 715.7 0.008* 122.78 ± 104.69 
CRP (mg/l) n.a. n.a. n.a. 4.93 ± 5.27 
SAP: stable angina pectoris, ACS: acute coronary syndrome, CAD: coronary artery disease, n.a.: not 
available. 
Asterisks (*) denote significant differences between SAP and ACS patient groups (p<0.05). 
Exceptions for sample numbers: total cholesterol, triglycerides (SAP: n=19, ACS: n=16); HDL-
cholesterol (SAP: n=18, ACS: n=16); LDL-cholesterol (SAP: n=18, ACS: n=15, stable CAD: n=22). 
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6.2. Special laboratory assays from blood samples 
6.2.1. Neuroendocrine markers: cortisol, ACTH, chromogranin A 
In study I., we tested the plasma values of cortisol and ACTH as neuroendocrine markers 
of stress. Raised plasma cortisol and grossly elevated ACTH levels in ACS patients showed 
that they were in a stressed state on admittance to the clinic; these values declined dramatically 
next day after PCI: plasma cortisol approximately halved (p<0.01) and ACTH value decreased 
by 85% (p=0.0001). Cortisol value of SAP patients resided in the normal range and did not 
change significantly among the observed time points, however, ACTH value also declined 
substantially in these patients the day after PCI (pre-PCI/1d-PCI: p<0.05, post-PCI/1d-PCI: 
p<0.01). Additionally, while the pre-PCI cortisol was considerably higher in the ACS group 
(p<0.05), the 1d-ACTH value was significantly higher in the SAP group than in the ACS one 
(p<0.01). We could demonstrate significant (statistical) interactions in the case of these stress 
hormones (cortisol: p<0.001, ACTH: p<0.05), this allowed us to compare the two groups. 
 
Figure 9. Plasma levels of ACTH and cortisol in CAD patients with stable angina pectoris (SAP, 
n=21) or with acute coronary syndrome (ACS, n=20) taken directly before, directly after and 
on the following day of percutaneous coronary intervention (PCI) (pre-, post- and 1d-PCI 
samples: Pre, Post, 1d). 
Data are means ± SEM. Several significant differences (Pre/1d, Post/1d; p*<0.05, p**<0.01, 
p****≤0.0001), and two significant intergroup differences (SAP vs. ACS) were found and shown 
(ACTH: 1d, px** = p**<0.01; cortisol: Pre, p*<0.05). The p values of interactions for ACTH: <0.03, 
and for cortisol: <0.001. 
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Pre-, post- and 1d-PCI values of plasma ACTH and cortisol of SAP and ACS patients are shown 
in Fig. 9, detailed data can be found in Table A3 in the annex section. 
In study II., plasma cortisol levels were in the normal range (294.45 ± 88.59 nmol/l), 
similarly as observed in SAP patients in the previous study. CgA exceeded the upper reference 
range limit of 153 ng/ml (178.81 ± 105.50 ng/ml) – given according to recent investigations of 
Glinicki et al. (2015) [114]. Data are presented in Table A4 as well (annex section). 
6.2.2. Special inflammatory markers in plasma: lactoferrin, IL-6, LL-37 
In study I., we employed lactoferrin and IL-6 as plasma inflammatory markers. After a 
moderate increase in post-PCI samples (p<0.001), plasma lactoferrin values fell to about 50% 
of the post-PCI levels next day after PCI (p<0.0001) in both groups. Both pre- and post-PCI 
plasma lactoferrin concentrations exceeded the upper physiological limit of 200 ng/ml. 
Alteration of plasma IL-6 values followed a different pattern: after a mild increase on the post-
PCI time point, it showed an about 2-fold elevation in 1d-PCI samples (pre-PCI/post-PCI: 
p<0.001, post-PCI/1d-PCI: p<0.0001). Pre-, post- and 1d-PCI values of plasma lactoferrin and 
IL-6 in SAP and ACS patients are shown in Fig. 10, detailed data can be found in Table A5 in 
the annex section. 
 
Figure 10. Plasma levels of lactoferrin and IL-6 directly before, directly after and on the 
following day of PCI in patients with stable angina pectoris (SAP, n=21; IL-6: n=18) or with 
acute coronary syndrome (ACS, n=20; IL-6: n=19, except: Post: n=18). 
Data are presented as means ± SEM; p***< 0.001, p****≤ 0.0001. The two patient groups were not 
statistically different (interaction p values > 0.3). 
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Beside the routinely measured plasma CRP, we chose to test IL-6 and LL-37 plasma 
levels in study II. to assess the general level of inflammation, and found that both of these 
marker values resided in the normal range (IL-6: 1.83 ± 1.35 pg/ml, LL-37: 55.31 ± 12.44 
ng/ml). Data are presented in Table A4 as well (annex section). 
6.2.3. Surface activation markers of granulocytes: L-selectin, CD15, lactoferrin in study 
I. 
 Concerning L-selectin signal intensity (MFI: mean fluorescence intensity), we found no 
time- and/or intervention-dependent associated changes. In the SAP group, L-selectin-bearing 
granulocyte proportion increased slightly during PCI (p<0.01) and decreased next day to about 
its initial value (p<0.05). Similarly, the percentage of CD15-carrier granulocytes raised 
somewhat during PCI (pre-PCI/post-PCI: p<0.05) and showed a gentle decline next day (post-
PCI/1d-PCI: p<0.0001) in both groups. Additionally, the 1d-PCI percentage of the CD15-
bearing cells decreased below the values measured on the initial time point (p<0.01) of both 
groups. CD15 MFI reduced slightly after PCI (p<0.05) in the ACS group, and furthermore, we 
could show a difference between groups in its 1d-PCI values (p<0.05).  
We observed more remarkable changes in the values of neutrophil-specific surface 
lactoferrin. Following PCI, the ratios of these lactoferrin-carrying cells fell to roughly half of 
their post-PCI values (post-PCI/1d-PCI: p<0.0001) in both groups. Similarly to the CD15-
bearing cell ratios, after a slight elevation during PCI (p<0.01), the proportions of surface 
lactoferrin-bearing cells were reduced considerably below the pre-PCI values (p<0.0001).  
Lactoferrin MFI altered less substantially, we found no significant elevation during PCI, 
however a considerable decline could be seen after PCI in both groups (post-PCI/1d-PCI: 
p<0.001). Pre-, post- and 1d-PCI values of the marker-bearing cell ratios and mean fluorescence 
intensities of granulocytes in SAP and ACS patients are shown in Fig. 11. (Detailed results can 
be found in Table A6 in the annex section.) 
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Figure 11. Ratios of marker-bearing cells (%) and mean fluorescence intensities (MFI) of 
granulocytes reflecting the cell surface appearance of activation markers directly before, 
directly after and on the following day of PCI (Pre, Post, 1d) in patients with stable angina 
pectoris (SAP, n=21) or with acute coronary syndrome (ACS, n=20; exception: 1d values, 
n=19). 
Data are presented as means ± SEM; p*<0.05, p**<0.01, p***<0.001, p****≤0.0001. 
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6.3. Psychosocial factors in study II. 
 Although the average depressive symptom level of the subjects was in the normal 
subclinical range (7.4 ± 9.4), seven patients (30%) had so high BDI scores that indicated the 
presence of clinically relevant depressive symptoms (five patients had mild, one patient had 
moderate and another one had severe symptoms). Interestingly, a subgroup analysis revealed 
that participants who took sedatives had significantly higher BDI scores than those who did not 
(12.8 ± 12.6 vs. 3.9 ± 4.4, p<0.05).  
The mean global stress-coping score yielded below zero (-0.7 ± 4.2), reflecting that the 
patients had higher stress than coping scores, however, its value was in the ‘sufficient’ range. 
Mean social support score was relatively low and close to reach the ‘sufficient’ range (7.9 ± 
2.4); the meaning of life score was evaluated as ‘good’ (11.9 ± 1.9). Data are presented in Table 
A4 as well (annex section). 
6.4. Correlations 
6.4.1. Correlations between stress hormones (cortisol, ACTH) and selected markers: 
percentage of lactoferrin-bearing neutrophils, plasma lactoferrin and IL-6 in study I. 
 As plasma lactoferrin, IL-6 and the ratio of surface lactoferrin-bearing cell values altered 
the most substantially, we examined the correlations of these inflammatory markers with the 
stress hormones (Table 7). Plasma ACTH showed inverse associations with the percentage of 
lactoferrin-carrying neutrophils (SAP: r= -0.601, p<0.005; ACS: r= -0.541, p<0.05) and with 
plasma lactoferrin in 1d-samples of both SAP and ACS groups (SAP: r= -0.435, p<0.05; ACS: 
r= -0.609, p<0.005). Furthermore, ACTH associated inversely with IL-6 in the pre-PCI sample 
of the SAP patient group (r= -0.483, p<0.05), and at the post-PCI time point of both groups as 
well (SAP: r= -0.487, p<0.05; ACS: r= -0.503, p<0.05). Surprisingly, cortisol correlated 
positively with plasma lactoferrin in the ACS group before the intervention (r= 0.499, p<0.05), 
but no other significant correlations were observed for this stress hormone in post- or 1d-PCI 
samples. 
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Table 7. Correlations between stress hormones and selected inflammatory markers 
Correlations between 
simultaneous data (parameter, 
time, patient group) 
Surface 
lactoferrin-bearing 
granulocytes (r) 
Plasma lactoferrin 
(r) 
Il-6 (r) 
ACTH - pre-PCI - SAP -0.283 (p=0.213) -0.158 (p=0.493) -0.483* (p=0.042) 
ACTH - pre-PCI - ACS  0.364 (p=0.115) 0.398 (p=0.082) -0.298 (p=0.215) 
Cortisol - pre-PCI - SAP 0.051 (p=0.827) 0.103 (p=0.658) -0.218 (p=0.385) 
Cortisol - pre-PCI - ACS 0.391 (p=0.088) 0.499* (p =0.025) -0.135 (p=0.581) 
ACTH - post-PCI - SAP -0.318 (p=0.160) -0.136 (p=0.557) -0.487* (p=0.040) 
ACTH - post-PCI - ACS  -0.044 (p=0.855) 0.051 (p=0.830) -0.503* (p=0.034) 
Cortisol - post-PCI - SAP -0.218 (p=0.342) 0.017 (p=0.942) 0.195 (p=0.438) 
Cortisol - post-PCI - ACS 0.083 (p=0.729) 0.217 (p=0.359) -0.329 (p=0.182) 
ACTH- 1d-PCI - SAP -0.601* (p=0.004) -0.435* (p=0.049) 0.024 (p=0.926) 
ACTH - 1d-PCI - ACS -0.541* (p=0.017) -0.609* (p=0.004) -0.068 (p=0.783) 
Cortisol - 1d-PCI - SAP -0.192 (p=0.404) -0.015 (p=0.950) 0.269 (p=0.280) 
Cortisol - 1d-PCI - ACS 0.281 (p=0.244) 0.250 (p=0.289) 0.254 (p=0.293) 
SAP: stable angina pectoris, ACS: acute coronary syndrome patients; pre-PCI: directly before, post-
PCI: directly after, and 1d-PCI: on the following day of PCI (stenting). 
Asterisks (*) denote significancy of correlations (p<0.05). 
SAP: n=21, ACS n=20; exceptions: IL-6 (ACS post-PCI: n=18, ACS pre- and 1-d-PCI: n=19) and 
percentage of lactoferrin-bearing cells (in ACS patients 1-day after PCI: n=19). 
6.4.2. Correlations between the MLR and psychosocial factors, neuroendocrine and 
inflammatory parameters in study II. 
 Bivariate analysis. Patients who had higher MLR values, had significantly higher levels 
of plasma CgA, LL-37, IL-6 and CRP (all p-values <0.03) with mostly large effect sizes (Table 
8). 
 Multivariate analysis. After adjusting for age, sex, and BMI (and proton pump inhibitor 
intake and NYHA grade for CgA models, as well), the effect sizes and significance of the 
correlations between the MLR and CgA, LL-37 improved greatly (r>0.6, p=0.003, 
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power>0.95). In contrast, these statistical values for IL-6 and CRP decreased or did not change 
substantially (r>0.45, p<0.04, power>0.65). Interestingly, the MLR associated with greater 
depressive symptom severity when further adjustment for sedative intake was employed in the 
model (r>0.6, p=0.004, power>0.95). As in the bivariate analysis, plasma cortisol and the two 
selected coping subscales of BSCI (social support, and purpose and connection) did not 
correlate significantly with the MLR. The significant multivariate-adjusted correlations 
between the MLR and PNI markers are shown in Fig. 12. 
 
Table 8. Correlations between the MLR and psycho-neuroendocrino-inflammatory system 
markers in stable CAD patients (n=23) 
  Bivariate correlations Multivariate correlations 
  r p power r p power 
Cortisol  0.279 n.s. 0.254 0.277 n.s. 0.251 
Chromogranin A 0.462* 0.026 0.664 0.660* 0.003 0.980 
LL-37  0.537* 0.010 0.811 0.643* 0.003 0.963 
IL-6 0.620* 0.002 0.951 0.532* 0.016 0.819 
CRP 0.474* 0.022 0.692 0.470* 0.036 0.683 
BDI 0.216 n.s. 0.173 0.624* 0.004 0.954 
BSCI social support 0.221 n.s. 0.180 -0.260 n.s. 0.234 
BSCI life meaning -0.124 n.s. 0.088 -0.084 n.s. 0.067 
r: Pearson’s correlation coefficient, BDI: Beck Depression Inventory, BSCI: Rahe’s Brief Stress and 
Coping Inventory, n.s.: not significant. 
Asterisks (*) denote significancy of correlations (p<0.05). 
Exceptions for sample number: n=22 for cortisol and LL-37. 
In the multivariate analysis, all parameters were adjusted for age, BMI and sex; additional adjustments 
for chromogranin A: intake of proton pump inhibitors and grades of heart failure; for BDI: intake of 
sedatives. 
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Figure 12. Multivariate-adjusted correlation plots of the MLR and PNI system markers in stable 
CAD patients (n=23) 
r2: square of the (Pearson) correlation coefficient, MLR: monocyte-to-lymphocyte ratio, CgA: 
chromogranin A, BDI: Beck Depression Inventory; exception for sample number: n=22 for LL-37. 
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6.4.3. Correlations amongst psychosocial factors, neuroendocrine and inflammatory 
factors in study II. 
 Both in the bivariate and multivariate model, we found significant and large effects for 
the association between lower social support scores and higher CgA plasma levels and between 
lower meaning in life and higher CRP plasma values (r< -0.45, all p-values<0.04, power>0.65), 
as can be seen in Table 9. Additionally, more severe depressive symptoms associated with 
higher LL-37 plasma concentrations (r>0.5, p<0.04, power>0.7) and especially strongly with 
elevated plasma CgA levels in the adjusted multivariate model (r>0.6, p<0.01, power>0.9). The 
significant multivariate-adjusted correlations among psychosocial factors, neuroendocrine and 
inflammatory markers are shown in Fig. 13. 
 
Table 9. Correlations amongst psychological/psychosocial factors and neuroendocrine and 
inflammatory markers in stable CAD patients (n=23) 
  Bivariate correlations Multivariate correlations 
  r p power r p power 
BDI - CgA  0.275 n.s. 0.258 0.618* 0.008 0.949 
BDI - LL-37  0.380 n.s. 0.45 0.502* 0.034 0.736 
BSCI social support - CgA -0.502* 0.015 0.756 -0.511* 0.030 0.776 
BSCI life meaning - CRP -0.555* 0.006 0.862 -0.467* 0.038 0.676 
r: Pearson’s correlation coefficient, BDI: Beck Depression Inventory, BSCI: Rahe’s Brief Stress and 
Coping Inventory, CgA: chromogranin A, n.s.: not significant. (Exception for sample number: n=22 for 
LL-37.) 
Asterisks (*) denote significancy of correlations (p<0.05). 
In the multivariate analysis, all parameters were adjusted for age, BMI and sex; additional adjustments 
for CgA: intake of proton pump inhibitors, grades of heart failure and for BDI: intake of sedatives. 
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Figure 13. Multivariate-adjusted correlation plots of psychological/psychosocial factors and 
neuroendocrine and inflammatory markers in stable CAD patients (n=23) 
r2: square of the (Pearson) correlation coefficient, CgA: chromogranin A, BDI: Beck Depression 
Inventory; exception for sample number: n=22 for LL-37. 
7. Discussion 
 Our main findings from study I. suggest that pre- and post-PCI states in both SAP and 
ACS patients may be associated with an increased ratio of activated/degranulated neutrophils 
expressing lactoferrin on their surface and releasing it. ACS patients were highly stressed and 
had an overactivated HPA axis; their plasma lactoferrin correlated with plasma cortisol before 
PCI. On the following day after PCI, both plasma lactoferrin and the ratio of surface lactoferrin-
bearing granulocytes decreased significantly in both groups, this could indicate declined 
granulocyte activation that may be due to the negative immune-modulatory effect of ACTH as 
suggested by negative correlations. 
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Our main findings from study II. is that increased MLR could be associated not only 
with inflammatory factors implicated in atherosclerosis, but with depressive symptoms and 
with elevated neuroendocrino-sympathetic activity (marked by increased plasma CgA) as well 
in stable CAD. Additionally, enhanced neuroendocrino-sympathetic activity was found to be 
associated with elevated depressive symptom level and with decreased social support. 
7.1. Stress and inflammatory parameters in CAD patients undergoing stenting 
 The highly elevated plasma cortisol level of ACS patients indicated that they were in an 
extremely stressed state before PCI; the substantially reduced plasma cortisol values on the day 
after PCI reflects a more relaxed state. Plasma cortisol of SAP patients remained mostly 
unreactive and did not change noticeably that may be due to a chronically overloaded, 
exhausted HPA axis [115]. The final low ACTH value of the ACS patients suggests that the 
initially overactivated HPA axis returned to a much more decreased, normal functioning state 
after stenting. The moderately decreased 1d-PCI plasma ACTH concentration of SAP patients 
could indicate a relief after stenting. The statistically significant alterations in plasma cortisol 
and ACTH values could not be due to the diurnal fluctuation, as the peaks of their concentration 
in blood are in the early morning (before 6 a.m.). 
 Leukocytes constitutively express L-selectin in their plasma membrane. In case of 
leukocyte activation, it is being cleaved from the cell surface, as can be seen in patients with 
unstable angina [96]. However, its increased cell surface presence may also accompany cell 
activation, e.g. after a mechanical trauma [116]. The ratio of L-selectin-bearing granulocytes in 
SAP patients increased slightly during PCI, then it decreased moderately, although these 
differences were not substantial, they were found to be statistically significant. These changes 
may reflect homeostatic alterations in these activated granulocytes (shedding balanced by 
reappearance). 
 CD15 (Lewis-X) is a tetrasaccharide ligand to selectins on the surface of all myeloid 
cells; neutrophils can mobilize it from their azurophilic/primary granules upon stimulation [52]. 
The ratio of CD15-carrying cells increased slightly directly after PCI (post-PCI samples of both 
groups). This statistically significant, though not considerable elevation may reflect modest late 
granulocyte activation (affecting primary granules) during stenting, independently of group. 
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The slight decrease on the following day suggests a less activated state, as in anxious patients 
in a relatively relaxed condition [76]. 
Lactoferrin is a specific activation marker of neutrophils: following cell activation and 
release form secondary granules, it can bound to cell surface and gain access to the circulation 
[46-48]. Similarly to the changes in the ratio of CD15-bearing cells, the proportion of 
lactoferrin-carrying neutrophils increased mildly directly after PCI. In parallel, plasma 
lactoferrin elevated slightly in post-PCI samples, which indicates slight neutrophil activation. 
One day after the intervention, marked reductions in cell surface and plasma lactoferrin values 
were observed in both patient groups that indicates a less activated state of neutrophils. Gach 
et al. (2005) observed a rapid rise of plasma lactoferrin in coronary artery blood directly after 
stenting in unstable angina patients that returned to its initial value in 6 hours [96]. Our pre-PCI 
values of surface lactoferrin-carrying neutrophils were also considerably high (>25%), showing 
an elevated ratio of activated neutrophils in CAD. Our findings on the increased plasma 
lactoferrin levels in pre-PCI samples are consistent with those of Videm et al. (2007), who 
suggested elevated plasma lactoferrin as a great marker for significant atherosclerotic coronary 
stenosis and showed that it is more reliable, than plasma myeloperoxidase, another neutrophil 
activation marker [45]. Furthermore, elevated baseline plasma lactoferrin may predict long-
term risk for fatal CAD in newly diagnosed diabetes patients that could be the consequence of 
the primed state of neutrophils, as suggested by Vengen et al. (2010) [117]. We found that 
plasma lactoferrin and the percentage of surface lactoferrin-bearing cells changed markedly and 
in a similar way in our patient groups; thus, both might be used as ‘neutrophil activity sensors’ 
in CAD patients. However, from a practical point of view, determining lactoferrin from plasma 
samples seems to be more suitable. (Blood plasma tests are less expensive and less complicated, 
and they could be probably automated.) 
 We found that plasma IL-6 increased during the intervention and enhanced especially 
on the following day of PCI; this could be a consequence of the onset of acute phase reaction. 
Similarly to our results, Gach et al. (2005) observed an increase of IL-6 during 6-12 hours after 
PCI in unstable angina patients in parallel with a decline of plasma lactoferrin and 
myeloperoxidase [96]. Furthermore, Caixeta et al. (2007) detected a significant, but moderate 
elevation of plasma IL-6 at 6 hours after PCI both in stable and unstable angina patients that 
was followed by a decrease; however, their study might have missed the peak at 24 h – as 
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suggested [97]. Circulating level of IL-6 has also a strong link with psychological stress in 
treated HIV-infected patients [118]. 
7.2. ACTH- and cortisol-associated neutrophil modulation in CAD patients 
undergoing stenting 
One of our main findings is that plasma ACTH and/or cortisol could be associated with 
the activation state of neutrophils in CAD. We showed inverse correlations between ACTH and 
surface lactoferrin-bearing granulocytes and plasma lactoferrin the following day of PCI in both 
groups. The supposition that ACTH could be capable to suppress neutrophil 
activation/degranulation is consistent with the concept of tonal inhibition of 
immune/inflammatory responsiveness by ACTH [119]. 
Cortisol and its analogues are well-known anti-inflammatory agents and immune 
suppressors, therefore, correlation of cortisol with plasma lactoferrin before stenting in ACS 
appears to be controversial. Still, glucocorticoids may be capable of activating human 
neutrophils in vitro; and owing to the high ratio of α to β type glucocorticoid receptors on them, 
neutrophils are less susceptible to apoptosis induction by these hormones [73,120]. Moreover, 
morning plasma cortisol levels were found to be associated with coronary atherosclerosis 
severity in US Air Force aircrew members and in patients with suspected CAD; thus, cortisol 
may be proposed as a proatherogenic stress factor [70,71]. Evidence is accumulating that 
selective inhibition of a cortisol-synthetizing enzyme (11β-hydroxysteroid dehydrogenase, 
11β-HSD1) may be useful in prevention of atherosclerosis [121,122]. Surprisingly, 11β-HSD1 
inhibition contributed to substantial prevention of aortic cholesterol accumulation in apoE-
deficient mice on high-fat diet [123]. On the other hand, cholesterol feeding for a month led to 
high cortisol values and to early signs of atherogenesis in rabbits, suggesting that vascular 
inflammation related to dyslipidemia may stimulate the HPA axis [124]. 
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7.3. The monocyte-to-lymphocyte ratio: a PNI correlate in stable CAD 
The elevated monocyte fraction and increased MLR reflects an inflammatory state in 
our stable CAD patients; this is supported by the correlations found between the MLR and 
plasma LL-37, IL-6 and CRP. Interestingly, the reciprocal of the MLR value (1/0.32 = 3.125) 
of our patients is almost equal to the critical lymphocyte-to-monocyte ratio of 3.1, characteristic 
for patients with a high risk of severe (atherosclerotic) limb ischemia, which is often 
accompanied by CAD [57]. 
The elevated circulating levels of chromogranin A (CgA) may suggest a general 
neuroendocrine overactivity with increased sympathoadrenal activity [80,81]. It should be 
noted, that we controlled our CgA models for the effect of proton pump inhibitors and 
myocardial release of CgA (in cardiac pressure/volume overload). Recently, Dutta et al. (2012) 
showed in apoE-deficient mice that elevated sympathetic activity is directly related to 
monocytosis through the enhanced release of hematopoietic cells from the bone marrow 
(mediated by norepinephrine and β3-adrenergic receptors) that was followed by increased 
monocytopoiesis in the spleen [125]. Monocyte release into blood stream could lead to the 
progression of atherosclerosis via promoting inflammation especially following myocardial 
infarction [125,126]. Accordingly, increased plasma CgA could reflect sympathetic activation 
that can lead to monocytosis in blood. This may be in the background of the highly significant 
correlation between CgA and the MLR. Furthermore, activated monocytes and macrophages 
are also capable to produce chromogranins [127]. 
About one-third of the participants had clinically relevant levels of depressive 
symptoms, and the average global stress-coping score was in the ‘sufficient’ range only, 
suggesting limited coping skills under stress amongst our patients. Patients with more severe 
depressive symptoms had higher plasma CgA levels, this could be explained by the increased 
activity of the neuroendocrino-sympathoadrenal system that accompanies depressive 
symptomatology. Previous studies found that depressed and chronically stressed subjects show 
sympathoadrenal hyperactivity that may lead to monocyte/macrophage activation via β-
adrenergic receptors in CAD [8, 128]. 
Proinflammatory cytokines (particularly IL-1) released by activated 
monocytes/macrophages may be involved in the background of the association between the 
MLR and depressive symptoms. These cytokines could contribute to the development of 
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depressive mood via interfering with neurotransmitter functioning [129,130]. Correlations of 
the MLR with IL-6 and CRP probably reflect the activated state of monocytes and their 
secretion of IL-6, the most potent inducer of CRP synthesis and acute phase response in general 
[90]. IL-6 and CRP are both major factors that are proposed as links between stress/depression 
and CAD [60,90,128]. According to Nikkheslat et al. (2015), depressed CAD patients could 
exhibit considerably higher plasma CRP and lower cortisol levels compared to CAD patients 
without depression [131]. Similarly, considerably high CRP and relatively low plasma cortisol 
levels were found in our patients that could be a result of long-term negative feedback in chronic 
stress [131,132]. 
The association observed between the MLR and LL-37 is not surprising, as monocytes 
and derived macrophages are known to release LL-37 in atherosclerotic lesions [98,101]. 
Recently, LL-37 has been proposed as a novel inflammatory marker; it is expressed by various 
leukocytes and has various antimicrobial and immunomodulatory effects, and it also takes part 
in apoptosis and wound healing [99]. Interestingly, LL-37 correlated significantly with 
depressive symptoms in our CAD patients; this supports the concept that a possible connection 
could exist between inflammation and depression [93]. 
Association of low social support with elevated CgA suggests that limited 
emotional/social support may lead to increased psychosocial stress and to elevated 
sympathoadrenal activity [133]. Based on mostly rodent investigations, Friedler et al. (2015) 
suggest that elevated sympathetic activity accompanying chronic psychosocial stress (e.g. 
social isolation) could drive hematopoiesis towards granulocytic/monocytic progenitor cell 
formation in bone marrow via β-adrenergic receptor-mediated signalling and altered gene-
expression [134]. This notion is in agreement with the mechanism of monocytosis mentioned 
above [125,126].  
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7.4. Principal findings 
One of our principal findings is that alteration in neutrophil activation state could be 
related to plasma ACTH and cortisol effects in CAD. In acute CAD patients, pre-PCI cortisol 
was elevated and correlated with plasma lactoferrin; the decreased 1d-PCI neutrophil activation 
markers, however, could reflect the negative immunomodulatory effect of ACTH. As high ratio 
of activated neutrophils can be considered as a risk factor for the initiation and progression of 
atherosclerosis [35], stress-related regulation of their activity bears considerable clinical 
importance.  
Another major finding is related to the PNI state of patients with stable CAD: we found 
that elevated MLR correlated with depressive symptoms, with raised sympathetic activity and 
with an inflammatory state that could be involved in the initiation and/or progression of CAD. 
Additionally, we found correlations between increased neuroendocrino-sympathetic activity 
and low social support and depressive symptom severity that could probably reflect the 
importance of the psychosocial state in stable CAD. Our present findings support some 
published results on the significance of sympathetic activation in monocytosis and in monocyte 
activation, and on the importance of psychological risk factors (e.g. limited social support) in 
CAD by promoting stress [8,125,126,128,133,135]. 
By integrating the above mentioned results and ideas, a simplified picture of a vicious 
cycle/network appears: stressed state before PCI or low social support could lead to raised HPA 
activity and predominant sympathetic activity, which then may facilitate neutrophil activation 
and could also lead to the elevation of the monocyte count and activity. Proinflammatory 
cytokines secreted by these activated neutrophils and monocytes facilitate the development of 
CAD and/or depression; with the development of CAD, the activity of the PNI network may be 
further elevated (e.g. through chest pain, stress and anxiety in angina pectoris). 
Therefore, our findings appear to underline the importance of stress management 
programs and psychosocial interventions, which are capable to reduce chronic stress, to boost 
social support and stress-coping skills and to alleviate depressive symptoms. These 
programs/interventions could favourably influence the vicious PNI cycle of interacting 
psychosocial factors, neuroendocrine and inflammatory markers, and thereby, they could 
effectively improve both the mental and physical health of the CAD patients [133,136]. 
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7.5. Limitations 
 Our research has a number of limitations. 
In study I., the exact background mechanisms of plasma ACTH and cortisol correlations 
with the inflammatory (neutrophil activation) state could not be fully clarified. Furthermore, 
some patient characteristics (e.g. life style factors, age, sex, pre-existent illnesses) may 
confound the presented results. It is known that metabolic syndrome could not only influence 
plasma ACTH values but it also frequently accompanies CAD [137,138]. However, our patient 
groups functioned as auto-controlled statistical units (repeated measurements within group, 
over-time comparisons), thus, these confounding factors had presumably only minor influence. 
Sample sizes of the groups were relatively small, however, the high levels of significances 
strengthen the validity of our findings. 
 In study II., the main limitations were the small sample size and its cross-sectional 
design. Still, large effect sizes of the statistically significant correlations support the validity of 
our results. Because of the small sample size, it was not possible to control for additional 
confounders, like established cardiovascular risk factors, smoking, diabetes, and medications 
(with the exceptions of proton pump inhibitors and sedatives). Average depressive symptom 
score remained in the normal range in the majority (70%) of participants; thus, it stays unclear 
whether our findings would hold true in a more severely depressed CAD patient sample or not. 
Because of the lack of a control group, the possibility that similar associations exist amongst 
the MLR, psychological and psychosocial factors, neuroendocrine and inflammatory markers 
in healthy subjects cannot be excluded. However, the increased monocyte fraction and the 
elevated MLR value, the overactivated neuroendocrino-sympathetic system (indicated by 
elevated plasma CgA), and the relatively low social support provide pathological characteristics 
of our stable CAD patients.  
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8. Conclusion 
Despite the discussed limitations, our first study led to interesting insights into the 
dynamically changing neutrophil behaviour in CAD patients undergoing PCI. We showed that 
neutrophils could be activated already before stenting, and till the next day of PCI, their 
activation state could decrease well below the initial values in both CAD groups. To our best 
knowledge, we are the first to reveal correlations between plasma ACTH, cortisol and 
neutrophil activation/degranulation state in CAD patients in connection with stenting. 
Additionally, we found that plasma lactoferrin could be a sensitive and valuable marker of 
neutrophil activation that deserves comprehensive methodological studies to evaluate it as a 
CAD risk marker. Furthermore, our second study revealed that the MLR, an easily available 
and inexpensive laboratory parameter, may be applied as a PNI correlate marker in the routine 
clinical monitoring of stable CAD patients. Further investigations are needed in this multi-
disciplinary field to clarify the detailed functional connections of the PNI network in CAD in 
order to facilitate the introduction and integration of innovative and more efficient approaches 
into prevention and treatment of atherosclerosis in the future. 
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L-selectin control            L-selectin sample (pre-PCI) 
Figure A8. Examples for flow cytometry measures: L-selectin control and sample (pre-PCI) results. 
  
Table A3. Stress hormone levels with statistical analysis in SAP and ACS patients in study I. (mean ± SD, p-values) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma levels of cortisol and ACTH in patients with stable angina pectoris (SAP) or with acute coronary syndrome (ACS); directly before, directly after and on 
the following day of PCI (Pre, Post, 1d). In case of SAP, n=21 and for ACS, n=20. 
a  the intragroup and intergroup differences were calculated by special contrasts, based on estimated marginal means; after the correction by step-down Bonferroni 
method; significant intragroup differences (p < 0.05 values) are denoted by asterisks (*); b in case of the presence of interaction (between groups), p values are 
given after the correction by step-down Bonferroni method; c p values of the two-way ANOVA; d ACTH statistical analysis: log-transformed data (ANOVA 
was performed on the logarithm of data). 
 
Parameters Sample results, significancy of intra- and intergroup differencesa ANOVA analysisc 
  Pre-PCI (1) Post-PCI (2) 1d-PCI (3) 
Separate 
intragroup 
pb 
Overall 
intragroup 
p 
Between 
groups 
(intergroup p) 
Interaction 
Cortisol (mmol/l)         0.001 0.0499 0.0006 
SAP 375.81 ± 173.66 450.00 ± 242.96 360.43 ± 183.71 0.706       
ACS 722.20 ± 440.56 595.80 ± 440.84 342.40 ± 193.99 0.006*       
ACS intragroup pb 1 vs 2: 0.184 2 vs 3: 0.060 1 vs 3: 0.002*         
SAP vs ACS pb 0.018* 0.610 0.762         
ACTH (pg/ml)d         0.0007 0.940 0.023 
SAP 55.56 ± 46.15 89.80 ± 76.65 35.64 ± 25.58 0.014*       
SAP intragroup pb 1 vs 2: 0.102 2 vs 3: 0.004* 1 vs 3: 0.03*         
ACS 122.60 ± 154.41 140.00 ± 158.03 18.79 ± 8.44 0.0001*       
ACS intragroup pb 1 vs 2: 0.507 2 vs 3: 0.0001* 1 vs 3: 0.0001*         
SAP vs ACS pb 0.544 0.544 0.007*         
  
 
 
 
Table A4. Plasma levels of special plasma markers and psychosocial scores of the SAP patients in study II. 
 
 
 
 
 
 
 
 
 
 
 
 
Variables are means ± SD. BSCI: Rahe’s Brief Stress and Coping Inventory.  
(n=23, exceptions for sample number: n=22 for cortisol and LL-37.)
  Parameter Value 
Neuroendocrine markers Cortisol (nmol/l) 294.45 ± 88.59 
Chromogranin A (ng/ml) 178.81 ± 105.50 
Inflammatory markers LL-37 (ng/ml) 55.31 ± 12.44 
IL-6 (pg/ml) 1.83 ± 1.35 
Psychosocial scores Beck Depression Inventory 7.4 ± 9.4 
BSCI Global stress-coping -0.7 ± 4.2 
BSCI Social support 7.9 ± 2.4 
BSCI Purpose and connection  11.9 ± 1.9 
  
 
 
Table A5. Plasma inflammatory markers with statistical analysis in SAP and ACS patients in study I. (mean ± SD, p-values) 
Plasma levels of lactoferrin and IL-6 in patients with stable angina pectoris (SAP) or with acute coronary syndrome (ACS); directly before, directly after and on 
the following day of PCI (Pre, Post, 1d). In case of SAP, n=21 (IL-6: n=18), and for ACS, n = 20 (IL-6: n=19, except: Post: n=18). 
a  the intragroup and intergroup differences were calculated by special contrasts, based on estimated marginal means; after the correction by step-down Bonferroni 
method; significant intragroup differences (p < 0.05 values) are denoted by asterisks (*); b in case of the presence of interaction (between groups), p values are 
given after the correction by step-down Bonferroni method; c p values of the two-way ANOVA.
Parameters Sample results, significances of intra- and intergroup differencesa ANOVA analysisc 
  Pre-PCI (1) Post-PCI (2) 1d-PCI (3) 
Separate 
intragroup 
pb 
Overall 
intragroup p 
Between 
groups 
(intergroup p) 
Interaction 
Plasma lactoferrin (ng/ml)        <0.0001 0.267 0.826 
SAP 241.86 ± 178.75 306.32 ± 193.49 137.69 ± 71.61         
ACS 282.10 ± 220.1 365.72 ± 220.47 205.33 ± 124.61         
SAP or ACS intragroup p 1 vs 2: 0.0008* 2 vs 3: <0.0001* 3 vs 1: 0.0008*         
Plasma IL-6 (pg/ml)        <0.0001 0.057 0.482 
SAP 1.52 ± 0.68 2.11 ± 1.16 4.26 ± 3.13         
ACS 2.31 ± 1.48 2.80 ± 1.88 5.99 ± 3.22         
SAP or ACS intragroup p 1 vs 2: 0.0009* 2 vs 3: <0.0001* 3 vs 1: <0.0001*         
  
 
Table A6. Appearance of special cell-surface inflammatory markers in SAP and ACS patients in study I. (mean ± SD, p-values) 
Percentages of surface marker-bearing granulocytes and mean fluorescence intensities (MFI) of granulocytes in patients with stable angina pectoris (SAP) or with acute coronary 
syndrome (ACS); directly before, directly after and on the following day of PCI (Pre, Post, 1d). In case of SAP, n=21 and for ACS, n=20 (except: 1d granulocyte values, n=19). 
For a, b and c: see Table A3.
Parameters Sample results, significancy of intra- and intergroup differencesa ANOVA analysisc 
  Pre-PCI (1) Post-PCI (2) 1d-PCI (3) 
Separate 
intragroup pb 
Overall 
intragroup p 
Between groups 
(intergroup p) 
Interaction 
L-selectin MFI        0.092 0.735 0.732 
SAP 94.01 ± 31.64 93.64 ± 27.01 82.39 ± 29.35         
ACS 88.10 ± 33.36 89.64 ± 34.89 80.79 ± 32.36         
L-selectin-bearing cells (%)         0.0002 0.613 0.147 
SAP 90.00 ± 8.92 93.71 ± 4.65 88.94 ± 10.50 0.001*       
SAP intragroup pb 1 vs 2: 0.001* 2 vs 3: 0.021* 1 vs 3: 0.557         
ACS 92.33 ± 8.34 93.53 ± 8.00 90.62 ± 11.59 0.302       
SAP vs ACS pb 1.000 1.000 1.000         
CD15 MFI         0.048 0.013 0.248 
SAP 75.78 ± 42.52 74.60 ± 32.24 68.19 ± 30.47 0.789       
ACS 53.38 ± 25.54 58.61 ± 27.25 44.89 ± 18.35 0.032*       
ACS intragroup pb 1 vs 2: 0.540 2 vs 3: 0.032* 3 vs 1: 0.17         
SAP vs ACS pb 0.332 0.332 0.032*         
CD15-bearing cells (%)        <0.0001 0.199 0.759 
SAP 87.88 ± 8.26 89.25 ± 8.29 74.59 ± 22.12         
ACS 79.86 ± 19.41 84.16 ± 18.16 68.33 ± 24.46         
SAP or ACS intragroup p 1 vs 2: 0.018* 2 vs 3: <0.0001* 3 vs 1: 0.002*         
Lactoferrin MFI        0.001 0.017 0.436 
SAP 52.06 ± 28.19  52.38 ± 25.25 34.48 ± 20.97         
ACS 34.25 ± 18.65 38.54 ± 16.51 27.45 ± 9.69         
SAP or ACS intragroup p 1 vs 2: 0.397 2 vs 3: 0.0006* 3 vs 1: 0.01*         
Lactoferrin-bearing cells (%)        <0.0001 0.322 0.376 
SAP 35.80 ± 25.14 38.62 ± 24.47 23.26 ± 21.23         
ACS 28.57 ± 20.31 35.74 ± 21.15 15.07 ± 13.98         
SAP or ACS intragroup p 1 vs 2: 0.008* 2 vs 3: <0.0001* 3 vs 1: <0.0001*         
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